hostile bid

Canada Rejects Takeover Bid for Potash

In a surprise decision by a government that has historically favored foreign investment, Canada has rejected a $38.6 billion foreign takeover bid for Saskatchewan-based Potash Corp.

Sanofi Denies Offering $69-$80 Price Range to Genzyme

There's a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than its current $69 bid -- a claim the French company disputes.

Sanofi-Aventis Launches Hostile Bid for Genzyme

After months of courting U.S. drugmaker Genzyme, French pharmaceutical company Sanofi-Aventis launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all outstanding shares of Genzyme common stock.

Avis Raises Its Bid for Dollar: Do 'Jumpers' Have an M&A Edge?

Avis Budget has increased its offer for Dollar Thrifty, firing the latest salvo in its bidding war for Dollar with archrival Hertz. It's a familiar pattern in the world of mergers and acquisitions, and the data shows that interlopers like Avis often a better chance of taking home the prize.

Air Products Lifts Airgas Offer to $65.50 a Share

Air Products & Chemicals (APD) has raised its bid for Airgas (ARG) to $65.50 a share in an all-cash offer. The latest offer represents a 50% premium above Airgas' closing stock price on Feb. 4, the day prior to Air Products submitting its first acquisition plan, Air Products said Monday in a written statement.

Sanofi-Avenits Won't Boost Genzyme Bid

Pharmaceutical giant Sanofi-Aventis is unwilling to pay more than $70 a share in its bid to buy biotech firm Genzyme, media outlets reported Wednesday. If a deal can't be reached, the French drugmaker may consider alternative takeover targets.